Citations

Clear

926 citation(s) found for "So, Jane".

Biliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors
Ghusn, Wissam , Abi-Aad, Sasha-Jane , Hurtado, Maria Daniela

Mayo Clinic

Journal of Clinical Medicine | October 16, 2026 | Volume: 15 | Issue: 20 | Pages: 8027

10.3390/jcm15208027 | PMID 42941539 Get It

To compare the 1-year risk of biliary/pancreatic adverse events among patients with obesity and type 2 diabetes treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus dipeptidyl peptidase-4 inhibitors (DPP-4i), and to directly compare tirzepatide with semaglutide. Methods: We conducted a retrospective propensity score-matched cohort study using the TriNetX Global Collaborative Network. Adults with obesity and type 2 diabetes without prior biliary or pancreatic disease were included. Two prespecified comparisons were performed: GLP-1RA (semaglutide or tirzepatide) versus DPP-4i, and tirzepatide versus semaglutide. The primary outcome was incident cholelithiasis at 1 year. Secondary outcomes included cholecystitis, cholangitis, acute pancreatitis, and cholecystectomy. Hazard ratios (HRs) were estimated using Cox proportional hazards models. Results: After matching, 281,283 patients were included in each GLP-1RA and DPP-4i cohort, and 242,876 patients in each tirzepatide and semaglutide cohort. Compared with DPP-4i, GLP-1RA therapy was associated with lower risks of cholelithiasis (1.02% vs. 1.16%; HR 0.92, 95%CI 0.87–0.96), cholecystitis (HR 0.88, 95%CI 0.79–0.98), cholangitis (HR 0.46, 95%CI 0.36–0.58), acute pancreatitis (HR 0.68, 95%CI 0.61–0.76), and cholecystectomy (HR 0.51, 95%CI 0.38–0.69). In the head-to-head comparison, semaglutide was associated with higher risks of cholelithiasis (HR 1.11, 95%CI 1.05–1.18) and cholecystitis (HR 1.22, 95%CI 1.10–1.37) compared with tirzepatide, while risks of pancreatitis, cholangitis, and cholecystectomy did not differ significantly. Conclusions: In this large real-world study, GLP-1RA therapy was associated with lower risks of biliary and pancreatic events compared with DPP-4i. Tirzepatide demonstrated a modestly more favorable biliary safety profile than semaglutide, supporting the overall hepatobiliary safety of contemporary GLP-1-based therapies.
Cortical surface area, thalamic nuclei volume, and associations with neurocognitive functioning in 6–13-year-old children born late preterm and full term
Nelson, Paige M. , Harmon, Heidi M., Brumbaugh, Jane E. , Nopoulos, Peg , Maller, Jerome J., Magnotta, Vincent A. , Nopoulos, Peggy C, Harmon, Heidi M. , Maller, Jerome J. , Momany, Allison M.

Mayo Clinic

No container title available | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.15.26362093 | PMID 42780114 Get It

Abstract Background Late preterm (LP) children (34 0/7 – 36 6/7 weeks of gestation) are at risk for neurocognitive challenges, yet the neuroanatomic and functional disruptions underlying these developmental differences remain poorly understood. Purpose or Hypothesis Investigate (1) regional differences in cortical surface area and thalamic nuclei volume and (2) structural variations that may explain heterogeneity in neurocognitive functioning in LP versus full term (FT) school-aged children, using two complementary approaches: a vertex-wise analysis of cortical surface area and a region-of-interest volumetric analysis of thalamic nuclei. Study Type Secondary analysis of a prospective observational cohort study. Population or Subjects 48 LP and 72 FT children aged 6–13 years. Field Strength/Sequence 3T; Sagittal T1-weighted MP-RAGE and axial T2-weighted 3D SPACE. Assessment FreeSurfer 7.4.1 was used to parcellate cortical regions (Destrieux atlas) and segment thalamic nuclei (25 nuclei). Neurocognitive functioning was assessed across four domains: hyperactivity/inattention (Pediatric Behavior Scale), processing speed (WISC-IV), working memory (WISC-III), and visual-spatial perception (Benton JLO). Statistical Tests Independent samples t-tests for group comparisons; vertex-wise GLMs for cortical surface analyses with false discovery rate (FDR) correction; and multiple linear regression for thalamic nuclei analyses with FDR-corrected q < 0.05. Results Vertex-wise analyses revealed regional differences in cortical surface area between LP and FT children in both hemispheres, along with associations between surface area in several cortical regions and hyperactivity/inattention, working memory, and visual-spatial perception. In contrast, using an ROI approach, thalamic nuclei volumes did not differ between groups and were not associated with any neurocognitive domains. Conclusion LP birth may be associated with subtle, region-specific bidirectional left and right hemispheric cortical surface area differences rather than widespread structural alterations in middle childhood, with regional macrostructural measures associated with individual differences in neurocognitive functioning.
Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics
Nabbout, Rima , Sullivan, Joseph , Auvin, Stéphane , Cross, J. Helen , Devinsky, Orrin , Guerrini, Renzo, Knupp, Kelly G. , Perry, Μ. Scott , Sánchez-Carpintero, Rocı́o , Scheffer, Ingrid E., Morita, Diego, Healy, Patrick, Langlois, Mélanie , Lagae, Lieven , Scheffer, Ingrid E. , Gil-Nagel, Antonio , Knupp, Kelly G , Perry, Michael Scott , Sánchez-Carpintero, Rocío , Schoonjans, An-Sofie , Specchio, Nicola , Strzelczyk, Adam , Wheless, James W , Wirrell, Elaine C , Lothe, Amélie , Lagae, Lieven , Auvin, Stéphane , Devinsky, Orrin , Cross, Helen J , Scheffer, Ingrid E , Gil‐Nagel, António , Guerrini, Renzo , Specchio, Nicola , Wheless, James W. , Wirrell, Elaine , Morita, Diego A. , Langlois, Mélanie

Mayo Clinic

Epilepsia Open | August 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi4.70340 | PMID 42632015 Get It

Abstract Objective To assess the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) stratified by age, number of previously attempted antiseizure medications (ASMs), and SCN1A pathogenic variant status. Methods In this post hoc analysis, data from three randomized controlled trials (RCTs) in patients with DS (2–18 years) were pooled and stratified by age (<4; ≥4 years), number of previous ASMs (1–3; 4–6; ≥7), and SCN1A pathogenic variant status ( SCN1A +; SCN1A −). Stratified groups were assessed and compared with the pooled placebo group (change in monthly convulsive seizure frequency [MCSF], longest convulsive seizure‐free interval, and Clinical Global Impression–Improvement [CGI–I] scale scores rated by parents/caregivers and investigators), and safety (treatment‐emergent adverse events [TEAEs]: frequency, days to onset, and proportion resolved). Results Among 348 patients included in the RCTs, 216 were randomized to fenfluramine (0.7 mg/kg/day, n = 88; 0.4 mg/kg/day [with stiripentol], n = 43; 0.2 mg/kg/day, n = 85) and 132 to placebo. Compared with placebo, fenfluramine treatment (all doses combined) resulted in greater MCSF reductions, greater increases in longest convulsive seizure‐free intervals, and a higher proportion of parents/caregivers and investigators reporting clinically meaningful improvement (“Much Improved”, “Very Much Improved”) on CGI–I scores across all stratified groups. CGI–I scores were consistent across fenfluramine doses in most stratified groups, but patients with the fewest number of previous ASMs had the greatest frequency of clinically meaningful improvement on investigator‐rated CGI–I scores. Safety outcomes were similar across all strata. Most TEAEs resolved by end‐of‐study. Significance Fenfluramine treatment was associated with improved seizure outcomes and global functioning compared with placebo regardless of age, number of previous ASMs, and SCN1A status in patients with DS. Fenfluramine was well‐tolerated; no new safety signals were identified. Further studies with larger sample sizes (including adults) and a priori inferential analyses of stratified groups are warranted. Plain Language Summary Patients with Dravet syndrome struggle with seizures and everyday life. In three studies, patients aged 2–18 years received fenfluramine or placebo (sugar pill). Fenfluramine lowered seizures without many side effects. Researchers combined results from these studies to see how fenfluramine worked in different patient groups based on age, number of previous medications, and a gene called SCN1A . They looked at seizure reduction and whether doctors felt patients had improved. In all groups, fenfluramine worked better than placebo, with similar side effects. Researchers believe fenfluramine helped these patients, but some groups were small, so these results need to be confirmed.
Expert consensus recommendations on appropriate treatment for telogen effluvium
Middleton, Hayden T. , Monahan, Erin, James, G, Franley, Brittney, Chavez, Magdalena, Kwong, Danny, Pham, Van, Griffith, Cynthia F. , Whinery, Sarah Jane, Blank, Alexander , Lightowler, Jennifer, Sledge, Eva, Griffith, Cynthia Faires , Link, Jenny

Mayo Clinic

Journal of Dermatology for Physician Assistants | August 21, 2026 | Volume: 20 | Issue: 3 | Pages: 8-13

10.1097/jdpa.0000000000000114 Get It

Background: Telogen effluvium (TE) is one of the most common forms of nonscarring alopecia. TE typically presents as sudden diffuse shedding of hair, and generally occurs 3–4 months after a triggering event such as physiological or psychological stress, certain medications, or hormonal changes. Despite the high prevalence of TE, no standardized clinical guidelines for the management of this condition currently exist. Objective: To address the lack of standard clinical guidelines for the management of TE, a multidisciplinary panel of dermatologists, dermatology advanced practice providers, and primary care providers convened to evaluate current evidence related to the treatment of TE. Methods: The primary research team, composed of 13 individuals, completed a comprehensive literature review of TE treatment. Then an expert panel conducted 2 rounds of article review, assessing each article based on the Strength of Recommendation Taxonomy (SORT) criteria and formulating consensus statements based on this data. An expert panel of 20 clinicians then evaluated the statements utilizing a structured eDelphi consensus process. Results: A total of 18 consensus statements regarding treatment recommendations for TE were reviewed by the expert panel. Of these, 3 statements addressed acute TE, while 15 focused on chronic TE. The panel evaluated each statement through open forum discussion, followed by voting and modification using the eDelphi methodology. Ultimately, 16 statements reached consensus following 2 rounds of the eDelphi survey. Conclusion: The self-limiting nature of acute TE warrants patient education, but no specific therapies were found to improve outcomes compared with placebo. While there is a gap in quality research regarding chronic TE treatment, current evidence suggests that topical minoxidil, vitamin D supplementation, and platelet-rich plasma may provide benefit in chronic TE based on individual clinical judgement.
Improving First-Attempt Success Rate During Neonatal Intubation in a Tertiary NICU
Kaczor, Mark , Wilhelm, Jayden, Bosley, Christopher, Schultz, Tammy, Schram, Laura, Gallup, Maria Cristina , Stetson, Raymond C. , Kaczor, Mark W., Brumbaugh, Jane E. , Wilhelm, Jayden M, Bosley, Christopher, Schultz, Tammy, Schram, Laura

Mayo Clinic

Pediatrics | August 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1542/peds.2025-074216 | PMID 42624503 Get It

BACKGROUND AND OBJECTIVES Neonatal tracheal intubation is a high-risk procedure, and multiple attempts are associated with adverse events. At our tertiary neonatal intensive care unit, the baseline first-attempt success rate was 45%, which we aimed to increase to over 55% through a quality improvement (QI) initiative. METHODS A multidisciplinary team conducted a QI project using the define-measure-analyze-improve-control framework. Root cause analysis identified poor glottic visualization and patient instability as primary drivers of failure. Plan-do-study-act cycles were carried out (April 2023–July 2024), followed by a sustainability phase (August 2024–May 2025). Key interventions included the phased implementation of video laryngoscopy (VL) as the primary intubation device and the standardization of oxygenation during laryngoscopy using nasal high flow. First-attempt success was tracked using statistical process control, and bimonthly VL use was monitored as a process measure. RESULTS A total of 642 intubations were analyzed. By control chart analysis, the first-attempt success rate increased from a baseline of 45% to a sustained process mean of 61% during the intervention and sustainability phases. VL use increased from 0% at baseline to 70% to 90% during the sustainability phase. Success rates improved across all clinician types and locations. Notably, first-attempt success in infants weighing less than 1000 g increased from 38% at baseline to 62% during the intervention phase. CONCLUSION A systematic QI initiative focused on VL and standardized oxygenation improved and sustained neonatal intubation success rates, exceeding the project aim. The maintenance of high-success rates confirms the durability of these safety improvements.
Evaluating longitudinal toxicity and adverse event in cetuximab-treated metastatic colorectal cancer: a pooled analysis from 1,302 patients in ARCAD database
Yin, Jun , Lopes, Guilherme S. , So, Jane, Olswold, Curt L., Cutsem, Eric Van, Bokemeyer, Carsten, Adams, Richard, Grothey, Axel, Yoshino, Takayuki, Gramont, Aimery de , Shi, Qian, Tournigand, Christophe , Zalcberg, John, Shi, Qian , Shi, Qian , Francis, Katherine E. , Lopes, Guilherme S, So, Jane , Cutsem, Eric Van , Bokemeyer, Carsten , Adams, Richard , Chibaudel, Benoist , Grothey, Axel , Yoshino, Takayuki , Sjoquist, Katrin Marie , Zalcberg, John

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag287 | PMID 42636265 Get It

Abstract Purpose Traditional adverse event (AE) reporting in oncology trials focuses on the single worst CTCAE grade, which may underrepresent chronic or recurrent toxicity burden. We applied a longitudinal toxicity framework to compare toxicity profiles of chemotherapy with or without cetuximab in metastatic colorectal cancer. Patients and Methods We pooled two randomized first-line trials in the ARCAD database. AEs examined were diarrhea, rash, hand-foot syndrome (HFS), fatigue, anorexia, and mucositis. Outcomes included grade ≥3 AE, time to first occurrence of maximum grade, early onset (≤6 weeks), and AEL, a normalized measure of cumulative toxicity burden over treatment. Analyses were adjusted for chemotherapy backbone, ECOG performance status, sex, primary tumor location, dose reduction, and treatment duration. Results Compared with Chemotherapy alone (n = 564), Chemotherapy plus cetuximab (n = 738) was associated with higher grade ≥3 rash (21% vs 0.5%; adjusted odds ratio [OR] 49.89, 95% CI 15.8–157.4), higher rash AEL (0.257 vs 0.069; adjusted mean difference 0.22, 95% CI 0.21–0.23), and more frequent early-onset maximum rash (67% vs 34%; adjusted OR 4.28, 95% CI 2.72–6.74). Rash AEL remained higher with cetuximab within maximum-grade strata. HFS showed higher grade ≥3 risk and overall AEL with cetuximab, but no within-grade AEL difference, indicating higher overall HFS burden reflected grade distribution rather than within-grade chronicity. No consistent differences were observed for other AEs. Conclusions Incorporating onset timing and AEL distinguished persistent toxicity burden from isolated peak events. This framework may support comparative tolerability assessment when chronic toxicity burden is central to decision-making.
Variability in recommending epilepsy surgery across Level IV epilepsy centers in the United States
Caraway, Avery R. , McNamara, Nancy A. , Knox, Andrew , Samanta, Debopam , Wolf, Steven M. , Novotny, Edward J., Ostendorf, Adam P. , Eschbach, Krista , Depositario‐Cabacar, Dewi F. , Pichon, Pilar, Auguste, Kurtis I., Bernardo, Danilo , Singh, Rani K., Ciliberto, Michael A., Reddy, Shilpa B., Arredondo, Kristen H. , Marashly, Ahmad , Galan, Fernando N., Armstrong, Dallas M., Wagner, Janelle L. , Wong-Kisiel, Lily C. , Bolton, Jeffrey B., Lin, Jenny, Coryell, J., Perry, Μ. Scott , Group, the rest of the PERC Surgery Special Interest, Galán, Fernando , Knox, Andrew T , Eschbach, Krista , Bernardo, Danilo , Grinspan, Zachary , Abel, Taylor J , Perry, Michael Scott , Galan, Fernando N , Wolf, Steven , McNamara, Nancy A., Novotny, Edward J. , Depositario‐Cabacar, Dewi, Karakas, Cemal , Auguste, Kurtis I. , Javarayee, Pradeep , Singh, Rani K., Ciliberto, Michael A. , Reddy, Shilpa B. , Armstrong, Dallas , Wong‐Kisiel, Lily C. , Bolton, Jeffrey , Grinspan, Zachary M. , Abel, Taylor J. , Coryell, Jason

Mayo Clinic

Epilepsia | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70440 | PMID 42621761 Get It

Abstract Objective Surgery is an effective, yet underutilized treatment for children with drug‐resistant epilepsy. Although predictors of surgical outcomes are well described, the decision to recommend surgery varies by institution. We aim to evaluate the rates of not recommending surgery, identify associated patient characteristics, and quantify variability across centers. Methods We queried the Pediatric Epilepsy Research Consortium Surgery database, a prospective multicenter cohort of children (0–18 years) undergoing initial evaluation for epilepsy surgery. Patients with documented surgical decisions were included. Demographic, clinical, and presurgical evaluation variables were compared by surgical recommendation status. Logistic regression identified factors associated with not recommending surgery. Mixed‐effects models quantified between‐center variability. Results Among 2480 patients across 29 centers, 532 (21%) were not recommended epilepsy surgery (median center rate 17%, interquartile range [IQR] 10%–28%). After accounting for patient characteristics associated with surgical candidacy, substantial variation in decision‐making remained across centers, with a median twofold difference in the odds of not recommending surgery between otherwise similar patients evaluated at different institutions (Median Odds Ratio = 2.25; Intraclass Correlation Coefficient = .18). The clinical characteristics most strongly associated with not recommending surgery included monthly or less frequent seizures (odds ratio [OR] 2.17, 95% confidence interval [CI] 1.75–2.69), non‐structural etiology (OR 2.02, 95% CI 1.56–2.61), and taking ≤2 anti‐seizure medications (ASMs) (OR 1.67, 95% CI 1.34–2.08, all p 's < .01). These characteristics showed minimal clustering across centers (ICCs < .05). Significance One in five children evaluated for epilepsy surgery are not recommended to pursue surgical treatment. Although clinical factors influence decision‐making, they do not explain the substantial variation in recommendations across pediatric epilepsy centers. Similar children evaluated at different institutions had significant differences in the odds of not being recommended surgery, suggesting that institutional decision‐making contributes importantly to surgical candidacy.
Long‐Term, Low‐Maintenance, and Impactful: Lessons Learned From Sustaining the NOHARM Pragmatic Clinical Trial
Gayathri, Shritha , Wicker, Alexandra Lauren , Hein, Jane , Nelson, Amanda, Cutshall, S, Cheville, Andrea, Tilburt, Jon, Courtright-Lim, Amanda , Wicker, Alexandra , Cutshall, Sue, Minteer, Sarah A.

Mayo Clinic

Learning Health Systems | August 17, 2026 | Volume: 10 | Issue: 4 | Pages: No page available

10.1002/lrh2.70075 | PMID 42610184 Get It

ABSTRACT Introduction Sustaining interventions implemented as part of pragmatic clinical trials requires proactive planning, but how to approach this process remains understudied. The Non‐pharmacological Options in Hospital‐based and Rehabilitation pain Management stepped‐wedge cluster‐randomized pragmatic trial tested an electronic health record‐based educational bundle (known as the Healing After Surgery [HAS] initiative) that encouraged the incorporation of non‐pharmacological pain care in perioperative pain management. The HAS initiative was implemented in multiple surgical practices and hospital sites. One year prior to trial completion, a sustainment committee was established to support the transition of intervention components to clinical ownership and to support posttrial sustainment of the HAS initiative. Methods We reviewed meeting minutes from biweekly sustainment committee meetings and conducted debriefing sessions with committee members (informed by the Clinical Sustainability Assessment Tool) to identify sustainment strategies and challenges, which were then organized into meaningful themes. Results The following six themes emerged from meeting minutes and debriefings: (1) automation of low‐touch components, (2) reliance on internal champions, (3) intentional handoff communication, (4) institutional attention, (5) relaxed fidelity, and (6) continuous evaluation. Together, they highlight the importance of early, structured planning and adaptable implementation strategies. Conclusions Sustainment of the HAS initiative required extensive communication, adaptation, and stakeholder engagement across diverse institutional contexts. Proactive sustainment planning during trial design may help ensure interventions are successfully integrated into routine clinical practice posttrial.
Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
Stevenson, James, Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R., Chang, Joe Y., Desai, Aakash, Dilling, Thomas J. , Dowell, Jonathan, Durm, Gregory A. , Gettinger, S., Grotz, Travis E., Gubens, Matthew A., Lackner, Rudy P., Lanuti, Michael, Levy, Benjamin, Loo, Billy W., Maldonado, Fabien, Morgensztern, Daniel , Mullikin, Trey C., Ng, Thomas, Owen, Dawn , Owen, Dwight H., Patil, Tejas, Polanco, Patricio M., Riess, Jonathan, Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P., Tam, Alda, Yau, Edwin, Yun, Karen, Gregory, Kristina, Hang, Lisa, Desai, Aakash , Desai, Aakash P , Axtell, Andrea L. , Bauman, Jessica R. , Bharat, Ankit , Gettinger, Scott , Grotz, Travis E. , Gubens, Matthew A. , Juloori, Aditya , Levy, Benjamin , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Maldonado, Fabien , Mullikin, Trey C. , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane , Yau, Edwin , Yun, Karen M. , Gregory, Kristina M., Hang, Lisa E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 17, 2026 | Volume: 24 | Issue: 8 | Pages: No page available

10.6004/jnccn.2026.0038 | PMID 42607715 Get It

Mesothelioma is a rare cancer that originates from the mesothelial surfaces of certain sites within the body. Pleural mesothelioma is the most common type and represents approximately 85% of mesotheliomas. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for evaluation and treatment in patients with pleural mesothelioma. The NCCN Guidelines will continue to be updated annually based on available clinical evidence and panel consensus.